No increase in febrile seizures with 2010-2011 TIV or PCV13

No increase in febrile seizures with 2010-2011 TIV or PCV13

(HealthDay)—For the 2010-2011 influenza season, there was no increase in the risk of febrile seizures (FS) with the trivalent inactivated influenza vaccine (TIV) or the 13-valent pneumococcal conjugate vaccine (PCV13), according to research published online Sept. 14 in Pediatrics.

Alison Tse Kawai, Sc.D, of Harvard Medical School in Boston, and colleagues examined the FS rate after TIV and PCV13 for a risk interval of zero to one days versus a control interval of 14 to 20 days as part of the Post-Licensure Rapid Immunization Safety Monitoring Program.

The researchers found no statistically significant TIV-FS associations in unadjusted or adjusted models. After adjusting for age and seasonality, PCV13 was significantly associated with FS (incidence rate ratio [IRR], 1.74; 95 percent confidence interval [CI], 1.06 to 2.86); but after further adjusting for concomitant TIV and diphtheria tetanus acellular pertussis-containing vaccines (DTaP), the association was not significant (IRR, 1.61; 95 percent CI, 0.91 to 2.82). Same-day vaccination with TIV and PCV13 was not associated with increased risk of FS compared with separate-day vaccination (1.08 fewer FS per 100,000 with same-day administration; 95 percent CI, −5.68 to 6.09).

"No statistically significant increased risk of FS was found for 2010-2011 TIV or PCV13, when adjusting for concomitant vaccines," the authors write. "Same-day TIV and PCV13 vaccination was not associated with more FS compared with separate-day vaccination."

Two authors disclosed financial ties to health insurance companies.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Pediatrics

Copyright © 2015 HealthDay. All rights reserved.

Citation: No increase in febrile seizures with 2010-2011 TIV or PCV13 (2015, September 15) retrieved 25 April 2024 from https://medicalxpress.com/news/2015-09-febrile-seizures-tiv-pcv13.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

PCV13 recommended for 6- to 18-year-olds at high risk

6 shares

Feedback to editors